Opioid Use Disorder May Soon be Treated With an Opioid Vaccine

First experimental vaccine against opioid use disorder is being tested in a phase 1a/1b clinical trial at Columbia

First experimental vaccine against opioid use disorder is being tested in a phase 1a/1b clinical trial at Columbia University Vagelos College of Physicians and Surgeons, Columbia, United States.

Almost 50,000 Americans died from opioid-related overdoses in 2019. Drug overdose (fentanyl and other synthetic opioids) deaths had cost the life of 87,000 people in 2020 during the pandemic as per the CDC.

Rise in Cardiac Arrests Linked to Opioid Use
The rate of opioid-related cardiac arrests has steeply risen. Opioid use disorder, which includes dependence and addiction, affects more than two million people in the US.

‘First experimental vaccine against opioid use disorder is being tested in a phase 1a/1b clinical trial at Columbia. Upon the successful trial, the oxycodone vaccine will be then tested in phase 2 and phase 3 trials to determine its efficacy. ’

“We have good medications to treat opioid use disorder, but about half of the people who use these medications relapse after about six months. A vaccine that lasts for several months, given in combination with any of these medications, could help many more people beat their addiction and potentially protect them from an overdose death if a patient relapses,” says Sandra Comer, Ph.D., professor of neurobiology in the Department of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons and principal investigator of the trial.

Opioid Vaccine

A common opioid analgesics called oxycodone is used to relieve moderate to severe pain. The chemical gets into the brain where it causes a euphoric feeling, or “high,”. The overuse of this drug may further impair the brain’s breathing centers and cause even death.

Traumatic Brain Injury Linked to Prescription Opioid Misuse
Adults with a history of traumatic brain injury (TBI) are at increased risk of use and misuse of prescription opioid medications.

The experimental vaccine is designed to generate antibodies against oxycodone and further prevent the oxycodone from getting into the brain. The vaccine also may protect against death from overdose due to respiratory depression.

The clinical trial aims to enroll 45 opioid users (currently being piloted in up to 24 volunteers) who are not receiving medication treatment for opioid use disorder.

Tool to Assess Cognitive Dysfunction in Opioid-dependent Patients
New simple and effective assessment tool helps quantify the risk of cognitive dysfunction in drug treatment programs risk for opioid-dependent patients.

One group of trial volunteers will be given a placebo; two other groups will receive either a low or high dose of the active vaccine. The trial aims to determine the toleration and safety level of the vaccine.

Efficacy of the Experiment

Apart from this, it also strives to explore the production of sufficient antibodies and the ability to prevent euphoria when the volunteers are given oxycodone. The pharmacokinetic and immunological monitoring in blood samples from participants is also undertaken to understand how the vaccine works.

“Vaccine development has been a tremendous boone to humanity. This innovative work brings it to bear on the scourge of addiction with the hope of having a great impact”, says Jeffrey A. Lieberman, MD, the Lawrence C. Kolb Professor of Psychiatry and chair of the Department of Psychiatry department at Columbia University Vagelos College of Physicians and Surgeons.

Upon the successful trial, the oxycodone vaccine will be then tested in phase 2 and phase 3 trials to determine its efficacy.

Source-Medindia